Skip to main content

United States News All stories

Every story in this section, newest first — page 145 of 373.

Grafa

Gilead Sciences gains EU approval for Trodelvy in first-line metastatic TNBC

Gilead Sciences (NASDAQ:GILD) announced that the European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) as monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer who have not received prior systemic therapy and are not candidates for PD-1 or PD-L1 inhibitor treatment.

Read more: Gilead Sciences gains EU approval for Trodelvy in first-line metastatic TNBC